Key takeaways:
- More than 400 patients have been enrolled in the LUCIA trial investigating Duravyu.
- EyePoint expects topline data from its phase 3 pivotal program in 2026.
LONG BEACH, Calif. — EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet age-related macular degeneration, according to a press release.
More than 400 patients have been enrolled in the trial and undergone randomization over the past 7 months. EyePoint’s first phase 3 trial of Duravyu, LUGANO, completed enrollment in May.
“These diseases are currently treated with short-acting ligand blockers, which do a very good job in the short term, but the big unmet need is prevention of visual loss in the long term,” Jay S. Duker, MD, president and CEO of EyePoint, told Healio at the American Society of Retina Specialists meeting.
Read more & Watch the Video: https://www.healio.com/news/ophthalmology/20250807/eyepoint-completes-enrollment-in-second-phase-3-trial-of-sustainedrelease-amd-therapy?utm_source=selligent&utm_medium=email&utm_campaign=20250810OSN&utm_content=20250810OSN
Source: Healio